AnteoTech (ASX:ADO) share price surges amid ambition to join scramble for RATs

The AnteoTech share price has started today on the right foot.

| More on:
health workers shake hands and congratulate each other on good news

Image source: Getty Images

Key points

  • The AnteoTech share price is up 4% in early morning trade.
  • The gain may relate to reports AnteoTech’s boss is hopeful its RAT device is in the final stages of TGA approval
  • The company’s reportedly preparing to ramp up production in Australia on the back of the regulator’s green light

The AnteoTech Ltd (ASX: ADO) share price is in the green this morning.

The gain comes amid reports AnteoTech plans to ramp up Australian production of its point-of-care rapid testing device as it awaits the Therapeutic Goods Administration’s (TGA’s) tick of approval.

At the time of writing, the AnteoTech share price is trading at 26.5 cents, 3.92% higher than its previous close.

AnteoTech shares climb as it readies for Australian approval

The AnteoTech share price is gaining after the company’s CEO Derek Thomson told ABC News it’s getting ready to hit the ground running as soon as its RAT is given the green light for use in Australia.

The Australia-based company is also reportedly prepared to push some of its tests produced in Spain into its home country until domestic manufacturing gets on its feet.

The ABC quoted Thomson as saying:

We can manufacture, currently, a small volume of tests here…

Our plan now, as Australian governments have indicated that RATs are going to be a frontline tool for the pandemic, is to scale up manufacturing here in Brisbane significantly over the next 9 to 12 months.

AnteoTech’s RAT works through its EuGeni Rapid Diagnostic Platform. It’s a point-of-care platform – meaning it can be operated by healthcare professionals. The company’s COVID-19 RAT is the first test to be used with EuGeni.

Thomson said AnteoTech had put an order in for equipment that could see it producing 12 million RAT strips annually in Australia. It expects production to start in the second quarter of 2022.

Additionally, he told the publication AnteoTech would be able to make more than that 12 million over the next 12 months, providing “a real sovereign manufacturing capability for the Australian market”.

Finally, Thomson noted the company’s tests could be in the final stages of TGA approval. He said AnteoTech was planning to supply more information to the regulator next week.

Spotlight on RATs

There’s plenty of other news likely putting the focus on RAT developers today.

Overnight, United States President Joe Biden announced the government will soon hand out 1 billion at-home RATs – meaning they’ll be out shopping for an additional 500 million tests.

Meanwhile, controversy surrounding the Australian Federal Government’s acquisition of RATs hit headlines today. If reports are correct, demand for RATs at retail outlets may well increase.

According to yesterday’s reporting by SBS, retailers claim the government seized their RAT orders at the point of import. The Department of Health has denied diverting supplies.

AnteoTech share price snapshot

The AnteoTech share price has had a rough start to 2022. Prior to today’s open, it had fallen 17% since the final close of last year.

However, shares in the company are currently trading 120% higher than this time last year.

Should you invest $1,000 in AnteoTech right now?

Before you consider AnteoTech, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and AnteoTech wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A smiling woman looks at her computer laptop in her home with warm lights in the background feeling happy to see the EMvision share price rising
Healthcare Shares

EMvision share price rockets 11% on $5 million pay day

Shares in the Australian medical device company shot higher today.

Read more »

retirement investing represented by older investor looking concerned at computer screen
Healthcare Shares

Why is the Medibank share price struggling to gain ground in May?

We check what's going on with shares in the private health insurer.

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Healthcare Shares

Here’s why the Imugene share price just got a boost

Imugene's latest announcement is rallying up investors.

Read more »

A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
Healthcare Shares

Why the AnteoTech share price is rocketing 33% today

What did AnteoTech update the ASX with?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Growth Shares

Why CSL shares are ‘going to deliver’ in 2022: fund manager

Quality growth companies can perform well even in an era of rising interest rates.

Read more »

a group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Incannex share price pops 9% on FDA news

The medicinal cannabis drug development company came out with some positive developments from its FDA meeting...

Read more »

Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory
Broker Notes

Where next for the CSL share price?

CSL shares could be heading higher according to one leading broker...

Read more »

A telehealth doctor at her desk.
Healthcare Shares

Why is the Ramsay share price smashing the ASX 200 on Monday?

Ramsay shares are off to a positive start today.

Read more »